- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Capasertib is a new AKT kinase inhibitor, which plays an anti-tumor role by targeting the inhibition of PI3K/AKT/mTOR signaling pathway. At pre...
As an AKT kinase inhibitor, the clinical application of Capivasortib requires strict adherence to specific restrictions, including contraindica...
Sparsentan has not yet been approved for marketing in Chinese Mainland. Patients need to obtain the drug through overseas channels, but they ne...
Sparsentan has not been listed in Chinese Mainland and has not been included in the national medical insurance reimbursement. If patients need ...
The standard method of taking elacestrant is once daily oral administration of 345mg (four tablets of 86mg each), which should be swallowed who...
The standard usage of elacestrant is once daily oral administration of 345mg, which should be taken as a whole tablet until disease progression...
Lomitamide, as a specific drug for the treatment of homozygous familial hypercholesterolemia (HoFH), has not been listed in Chinese Mainland an...
Lomitapide, as a microsomal triglyceride transfer protein (MTP) inhibitor, has significant therapeutic effects on homozygous familial hyperchol...
Fumarate propofol tenofovir tablets (Vemlidy) are a novel nucleotide reverse transcriptase inhibitor mainly used for the treatment of chronic h...
Fumarate propofol tenofovir tablets (Vemlidy) are a novel antiviral drug primarily used for the treatment of chronic hepatitis B virus infectio...
